Triamcinolone acetonide

Suprachoroidal injection of triamcinolone acetonide (Xipere) for treatment of macular edema associated with noninfectious uveitis in adults (≥18 years) is covered. Coverage is limited to the FDA‑approved indication and administration (SCS Microinjector, ≤4 mg per affected eye), excludes infectious uveitis and patients <18, and off‑label uses require two qualifying peer‑reviewed articles and are otherwise considered experimental; member benefit plans and state/plan-specific limits apply.

"Requested therapies that are proven effective for the relevant diagnosis or procedure."

Sign up to see full coverage criteria, indications, and limitations.